Welcome to the news headquarters for Kymanox. Releases are listed in chronological order, starting at the top with the most recent news. If you desire more information on a specific topic or have a question or comment, please send email correspondence to email@example.com or visit the contact page for more options.
06MAR17: Kymanox Expands, Signs New Director of Manufacturing Operations
Richard Motruk joins Kymanox as new Director of CGMP Manufacturing
Research Triangle Park, North Carolina, United States | Monday, 06 March 2017 | Kymanox adds experienced operations leader, Richard Motruk, to its team
Richard Motruk has over 15 years of combined experience in the biopharmaceutical and medical device industries. He earned a Bachelor of Science in Biochemistry and Molecular Biology from Penn State University. He brings his proven expertise leading both technical and operations-focused teams, small and large, to Kymanox and their client base.
In regards to his new employment at Kymanox, Mr. Motruk expressed his excitement in being able to leverage his diverse Life Science experience to assist clients improve their operational efficiencies while maintaining or exceeding their quality and compliance levels. 'Kymanox is highly regarded for its expertise in many facets of CGMP manufacturing, chemistry, and related controls. The idea of joining an industry leader, and being able to parlay my operational leadership experience gained at bioMerieux, Teva, and OraSure, is very exciting,' he said.
Richard is a welcome addition to the Kymanox team, CEO and Founder Stephen M. Perry remarked. 'With Richard now directing our established Process Operations and Validation groups, this new leadership position lays a solid foundation for future, sustainable growth,' he said. 'This helps make the Kymanox team even more capable to address challenges with bringing modern medicines to patients in need across the globe.'
07OCT16: Kymanox Relationships
R E L A T I O N S H I P S
By Nathan Blazei, MEng, ASQ CQA
Senior Manager, Quality + Compliance
As an engineering and compliance service provider in the life science industry, we are tasked with building and maintaining positive relationships every day. Positive relationships take time, commitment, honesty, trust, and openness to build and maintain. They are mutually beneficial, unassuming, and resilient. When relationships are ignored, taken advantage of, de-prioritized, or otherwise suffer, it can have a devastating effect on a business and ultimately the patient communities we all aim to serve.
This may sound intuitive, however there are few industries that have the complexity of relationships that we experience in the life sciences. We work in a field that has many interconnected parts that are sometimes at conflict with one another. The expectations are so incredibly high, and the margin for error is razor thin. Life science companies have to provide mutual benefit to our employees, our investors, our shareholders, our patient communities, our medical professionals, our insurance providers, our business partners, and our governments at the same time. And the goals of each of these stakeholders are not always aligned, which makes the job at hand all the more challenging.
We have seen a prime example of the challenge to building and maintaining positive relationships recently with the EpiPen from Mylan, which is used for emergency treatment of severe allergic reactions. As a parent of a child with a severe peanut allergy, I am obligated to have EpiPens on hand at all times. My son has them at school, we have them at home, and we take them with us everywhere we go. And right now there are few, if any, reliable alternatives to consider. As the EpiPen's price continues to rise, Mylan runs the risk of not being able to get EpiPens into the hands of those in our community who need them for survival.
Mylan is facing intense public scrutiny because of what could in many ways be traced back to poor relationship management. While the debate continues and the government mulls its options for how to address this situation, one is left to wonder if Mylan lost sight of the goals of some of their stakeholders in favor of those of others. Right or wrong, they are now under the microscope of an entire nation. Where they go from here will have a profound impact on the many relationships they have built over the years. And some will likely never recover.
At Kymanox, we put tremendous value on building and maintaining positive relationships with our employees, our clients, our business partners, our community, our government, and the various patient populations we serve. We understand the challenge of working in this industry and we know the expectations are always sky high. We embrace that challenge, and we look forward to building and maintaining a positive relationship with all of you in the years to come in order to continue advancing modern medicine together.
22JAN16: Kymanox welcomes Ayman Tamimi
Kymanox is pleased to announce the on-boarding of Mr. Ayman Tamimi for the position of Associate Project Engineer. In the Technical Project Management group, he will be ensuring that deliverables continue to exceed client expectations. Ayman will soon complete his Bachelor of Science degree in Chemical Engineering at North Carolina State University (www.ncsu.org).